1. Zealand Pharma announced total shares and voting rights as of December 31, 2025. 2. Total shares increased to 71,515,045 due to employee warrants exercise. 3. The company focuses on obesity and metabolic health advancements. 4. Zealand Pharma has multiple drug candidates in clinical development. 5. Their proprietary data platform leverages AI/ML for drug development.
FAQ
Why Neutral?
The share capital increase may dilute existing shares but has no immediate adverse effects. Historically, similar announcements have not led to drastic price changes.
How important is it?
The announcement is pertinent for understanding share dynamics, but lacks significant market catalysts. Potential impacts from ongoing clinical trials could overshadow this event soon.
Why Short Term?
The increase in shares will have a short-term impact on stock value perception. Long-term effects depend on clinical developments and product launches.
Total Number of Shares and Voting Rights in Zealand Pharma as of December 31, 2025
Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) has announced the total number of shares and voting rights as of December 31, 2025. This announcement is in compliance with section 32 of the Danish Capital Markets Act, following a month in which changes to the Company's share capital occurred.
Overview of Share Capital Changes
In Company Announcement No. 25 / 2025 dated December 11, 2025, Zealand Pharma disclosed a share capital increase resulting from the exercise of employee warrants. The details of the shares and voting rights are as follows:
- Date: December 31, 2025
- Number of Shares: 71,515,045 (nominal value of DKK 1 each)
- Share Capital: 71,515,045 (nominal value in DKK)
- Number of Voting Rights: 71,515,045
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) specializes in developing innovative medicines focused on obesity and metabolic health. With over 25 years of expertise in peptide research and development (R&D), the Company utilizes a proprietary data platform that incorporates advanced data-driven and artificial intelligence/machine learning approaches.
To date, Zealand Pharma has seen over ten drug candidates enter clinical development, with two products successfully reaching the market and three candidates currently in late-stage development. The Company collaborates with global pharmaceutical and biotechnology partners to enhance research, development, and commercialization efforts.
Company Information and Contact
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, and has a U.S. presence in Boston, Massachusetts. For more information, visit the Company’s website at www.zealandpharma.com.
Media and Investor Contacts
- Adam Lange
Vice President, Investor Relations
Email: alange@zealandpharma.com - Neshat Ahmadi
Investor Relations Manager
Email: neahmadi@zealandpharma.com - Rachel James-Owens
Vice President, Corporate Communications & Media Relations
Email: RJamesOwens@zealandpharma.com